Ymkje Stienstra

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6627888/publications.pdf

Version: 2024-02-01

111 papers	3,529 citations	159585 30 h-index	155660 55 g-index
115 all docs	115 docs citations	115 times ranked	3048 citing authors

#	Article	IF	Citations
1	Effect of Azithromycin Maintenance Treatment on Infectious Exacerbations Among Patients With Nonâ€“Cystic Fibrosis Bronchiectasis. JAMA - Journal of the American Medical Association, 2013, 309, 1251.	7.4	421
2	Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet, The, 2010, 375, 664-672.	13.7	258
3	Risk Factors for Buruli Ulcer Disease (Mycobacterium ulcerans Infection): Results from a Case-Control Study in Ghana. Clinical Infectious Diseases, 2005, 40, 1445-1453.	5.8	138
4	Histopathologic Features ofMycobacterium ulceransInfection. Emerging Infectious Diseases, 2003, 9, 651-656.	4.3	134
5	Beliefs and attitudes toward Buruli ulcer in Ghana.. American Journal of Tropical Medicine and Hygiene, 2002, 67, 207-213.	1.4	131
6	Quality of interhospital transport of critically ill patients: a prospective audit. Critical Care, 2005, 9, R446.	5.8	123
7	Mycobacterium ulcerans disease. Bulletin of the World Health Organization, 2005, 83, 785-91.	3.3	114
8	Paradoxical Responses After Start of Antimicrobial Treatment in Mycobacterium ulcerans Infection. Clinical Infectious Diseases, 2012, 54, 519-526.	5.8	91
9	Mycolactones and Mycobacterium ulcerans disease. Lancet, The, 2003, 362, 1062-1064.	13.7	78
10	Susceptibility to development of Mycobacterium ulcerans disease: review of possible risk factors. Tropical Medicine and International Health, 2001, 6, 554-562.	2.3	74
11	Susceptibility to Buruli ulcer is associated with the SLC11A1 (NRAMP1) D543N polymorphism. Genes and Immunity, 2006, 7, 185-189.	4.1	71
12	Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial. Lancet, The, 2020, 395, 1259-1267.	13.7	71
13	Early atherosclerosis in systemic sclerosis and its relation to disease or traditional risk factors. Arthritis Research and Therapy, 2008, 10, R49.	3.5	59
14	Long Term Streptomycin Toxicity in the Treatment of Buruli Ulcer: Follow-up of Participants in the BURULICO Drug Trial. PLoS Neglected Tropical Diseases, 2014, 8, e2739.	3.0	56
15	A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs. Clinical Pharmacokinetics, 2019, 58, 747-766.	3.5	53
16	Factors associated with functional limitations and subsequent employment or schooling in Buruli ulcer patients. Tropical Medicine and International Health, 2005, 10, 1251-1257.	2.3	50
17	Functional Limitations after Surgical or Antibiotic Treatment for Buruli Ulcer in Benin. American Journal of Tropical Medicine and Hygiene, 2009, 81, 82-87.	1.4	49
18	Healthcare seeking behaviour for Buruli ulcer in Benin: a model to capture therapy choice of patients and healthy community members. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2008, 102, 912-920.	1.8	48

#	Article	IF	Citations
19	Cytokine Responses to Stimulation of Whole Blood from Patients with Buruli Ulcer Disease in Ghana. Vaccine Journal, 2005, 12, 125-129.	3.1	47
20	In-vitro Activity of Avermectins against Mycobacterium ulcerans. PLoS Neglected Tropical Diseases, 2015, 9, e0003549.	3.0	46
21	Variability of antibiotic susceptibility and toxin production of Staphylococcus aureus strains isolated from skin, soft tissue, and bone related infections. BMC Microbiology, 2013, 13, 188.	3.3	45
22	Assessment of functional limitations caused by Mycobacterium ulcerans infection: towards a Buruli Ulcer Functional Limitation Score. Tropical Medicine and International Health, 2003, 8, 90-96.	2.3	41
23	Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial. Journal of Antimicrobial Chemotherapy, 2016, 71, 703-710.	3.0	41
24	Buruli ulcer: differences in treatment outcome between two centres in Ghana. Acta Tropica, 2003, 88, 51-56.	2.0	40
25	Analysis of an IS 2404 -Based Nested PCR for Diagnosis of Buruli Ulcer Disease in Regions of Ghana Where the Disease Is Endemic. Journal of Clinical Microbiology, 2003, 41, 794-797.	3.9	38
26	Contribution of the Community Health Volunteers in the Control of Buruli Ulcer in BÃ©nin. PLoS Neglected Tropical Diseases, 2014, 8, e3200.	3.0	38
27	Divergent approaches in the vaccination of recently arrived migrants to Europe: a survey of national experts from 32 countries, 2017. Eurosurveillance, 2018, 23, .	7.0	36
28	Buruli Ulcer Control in a Highly Endemic District in Ghana: Role of Community-Based Surveillance Volunteers. American Journal of Tropical Medicine and Hygiene, 2015, 92, 115-117.	1.4	35
29	Functional limitations after surgical or antibiotic treatment for Buruli ulcer in Benin. American Journal of Tropical Medicine and Hygiene, 2009, 81, 82-7.	1.4	34
30	High prevalence of MRSA and ESBL among asylum seekers in the Netherlands. PLoS ONE, 2017, 12, e0176481.	2.5	33
31	Initiation and completion of treatment for latent tuberculosis infection in migrants globally: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2021, 21, 1701-1712.	9.1	32
32	Mean glucose level is not an independent risk factor for mortality in mixed ICU patients. Intensive Care Medicine, 2006, 32, 435-438.	8.2	31
33	Delayed versus standard assessment for excision surgery in patients with Buruli ulcer in Benin: a randomised controlled trial. Lancet Infectious Diseases, The, 2018, 18, 650-656.	9.1	31
34	High Prevalence of Infectious Diseases and Drug-Resistant Microorganisms in Asylum Seekers Admitted to Hospital; No Carbapenemase Producing Enterobacteriaceae until September 2015. PLoS ONE, 2016, 11, e0154791.	2.5	30
35	Distribution of Buruli ulcer lesions over body surface area in a large case series in Ghana: uncovering clues for mode of transmission. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2005, 99, 196-201.	1.8	29
36	Dynamics of Parasite Clearance in Cutaneous Leishmaniasis Patients Treated with Miltefosine. PLoS Neglected Tropical Diseases, 2011, 5, e1436.	3.0	29

#	Article	IF	Citations
37	Longitudinal Echocardiographic Followâ€Up in Children with Congenital Complete Atrioventricular Block. PACE - Pacing and Clinical Electrophysiology, 2007, 30, 1339-1343.	1.2	28
38	Wound Care in Buruli Ulcer Disease in Ghana and Benin. American Journal of Tropical Medicine and Hygiene, 2014, 91, 313-318.	1.4	28
39	Efficacy of ivermectin mass-drug administration to control scabies in asylum seekers in the Netherlands: A retrospective cohort study between January 2014 â€“ March 2016. PLoS Neglected Tropical Diseases, 2018, 12, e0006401.	3.0	28
40	No effects of bosentan on microvasculature in patients with limited cutaneous systemic sclerosis. Clinical Rheumatology, 2009, 28, 825-833.	2.2	27
41	Persisting Social Participation Restrictions among Former Buruli Ulcer Patients in Ghana and Benin. PLoS Neglected Tropical Diseases, 2014, 8, e3303.	3.0	27
42	â€˜The medicine is not for saleâ€™: Practices of traditional healers in snakebite envenoming in Ghana. PLoS Neglected Tropical Diseases, 2021, 15, e0009298.	3.0	25
43	Epidemiology of Staphylococcus aureus in a burn unit of a tertiary care center in Ghana. PLoS ONE, 2017, 12, e0181072.	2.5	25
44	Towards Rational Use of Antibiotics for Suspected Secondary Infections in Buruli Ulcer Patients. PLoS Neglected Tropical Diseases, 2013, 7, e2010.	3.0	24
45	Sensitivity and specificity of an electronic nose in diagnosing pulmonary tuberculosis among patients with suspected tuberculosis. PLoS ONE, 2019, 14, e0217963.	2.5	24
46	National approaches to the vaccination of recently arrived migrants in Europe: A comparative policy analysis across 32 European countries. Travel Medicine and Infectious Disease, 2019, 27, 33-38.	3.0	23
47	High prevalence of multidrug-resistant tuberculosis among patients with rifampicin resistance using GeneXpert Mycobacterium tuberculosis/rifampicin in Ghana. International Journal of Mycobacteriology, 2016, 5, 226-230.	0.6	22
48	Genetic Susceptibility and Predictors of Paradoxical Reactions in Buruli Ulcer. PLoS Neglected Tropical Diseases, 2016, 10, e0004594.	3.0	22
49	RELIABILITY AND VALIDITY OF THE BURULI ULCER FUNCTIONAL LIMITATION SCORE QUESTIONNAIRE. American Journal of Tropical Medicine and Hygiene, 2005, 72, 449-452.	1.4	22
50	Immunoglobulin M Antibody Responses to Mycobacterium ulcerans Allow Discrimination between Cases of Active Buruli Ulcer Disease and Matched Family Controls in Areas Where the Disease Is Endemic. Vaccine Journal, 2004, 11, 387-391.	2.6	21
51	Genetic Diversity of Staphylococcus aureus in Buruli Ulcer. PLoS Neglected Tropical Diseases, 2015, 9, e0003421.	3.0	21
52	Former Buruli Ulcer Patientsâ€™ Experiences and Wishes May Serve as a Guide to Further Improve Buruli Ulcer Management. PLoS Neglected Tropical Diseases, 2016, 10, e0005261.	3.0	21
53	The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection. European Respiratory Journal, 2015, 45, 569-571.	6.7	20
54	DEVELOPMENT OF A QUESTIONNAIRE ASSESSING BURULI ULCERâ€“INDUCED FUNCTIONAL LIMITATION. American Journal of Tropical Medicine and Hygiene, 2004, 70, 318-322.	1.4	20

#	Article	IF	Citations
55	Optimal Sampling Strategies for Therapeutic Drug Monitoring of First-Line Tuberculosis Drugs in Patients with Tuberculosis. Clinical Pharmacokinetics, 2019, 58, 1445-1454.	3.5	19
56	Moxidectin and Ivermectin Inhibit SARS-CoV-2 Replication in Vero E6 Cells but Not in Human Primary Bronchial Epithelial Cells. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0154321.	3.2	19
57	Good Quality of Life in Former Buruli Ulcer Patients with Small Lesions: Long-Term Follow-up of the BURULICO Trial. PLoS Neglected Tropical Diseases, 2014, 8, e2964.	3.0	18
58	Pharmacologic management ofMycobacterium ulceransinfection. Expert Review of Clinical Pharmacology, 2020, 13, 391-401.	3.1	16
59	Virulence potential of Staphylococcus aureus isolates from Buruli ulcer patients. International Journal of Medical Microbiology, 2017, 307, 223-232.	3.6	15
60	Sensitivity and specificity of routine diagnostic work-up for tuberculosis in lung clinics in Yogyakarta, Indonesia: a cohort study. BMC Public Health, 2019, 19, 363.	2.9	15
61	Asylum seekersâ€™ perspectives on vaccination and screening policies after their arrival in Greece and The Netherlands. PLoS ONE, 2019, 14, e0226948.	2.5	15
62	High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	15
63	Perceptions on the Effectiveness of Treatment and the Timeline of Buruli Ulcer Influence Pre-Hospital Delay Reported by Healthy Individuals. PLoS Neglected Tropical Diseases, 2013, 7, e2014.	3.0	14
64	Management of <scp>BU</scp>â€“<scp>HIV</scp> coâ€infection. Tropical Medicine and International Health, 2014, 19, 1040-1047.	2.3	14
65	BURULI ULCER AND SCHISTOSOMIASIS: NO ASSOCIATION FOUND. American Journal of Tropical Medicine and Hygiene, 2004, 71, 318-321.	1.4	13
66	Molecular Characterization of Staphylococcus aureus Isolates Transmitted between Patients with Buruli Ulcer. PLoS Neglected Tropical Diseases, 2015, 9, e0004049.	3.0	12
67	Proportion of asylum seekers carrying multi-drug resistant microorganisms is persistently increased after arrival in the Netherlands. Antimicrobial Resistance and Infection Control, 2019, 8, 6.	4.1	12
68	Development of a questionnaire assessing Buruli ulcer-induced functional limitation. American Journal of Tropical Medicine and Hygiene, 2004, 70, 318-22.	1.4	12
69	Methicillin Resistant Staphylococcus aureus Transmission in a Ghanaian Burn Unit: The Importance of Active Surveillance in Resource-Limited Settings. Frontiers in Microbiology, 2017, 8, 1906.	3.5	11
70	Screening for infectious diseases of asylum seekers upon arrival: the necessity of the moral principle of reciprocity. BMC Medical Ethics, 2018, 19, 16.	2.4	11
71	Practices of therapeutic drug monitoring in tuberculosis: an international survey. European Respiratory Journal, 2022, 59, 2102787.	6.7	11
72	Psychometric Properties of the Participation Scale among Former Buruli Ulcer Patients in Ghana and Benin. PLoS Neglected Tropical Diseases, 2014, 8, e3254.	3.0	10

#	Article	IF	Citations
73	Pain Associated with Wound Care Treatment among Buruli Ulcer Patients from Ghana and Benin. PLoS ONE, 2015, 10, e0119926.	2.5	10
74	Compliance with Antimicrobial Therapy for Buruli Ulcer. Antimicrobial Agents and Chemotherapy, 2014, 58, 6340-6340.	3.2	9
75	The Application of Modern Dressings to Buruli Ulcers: Results from a Pilot Implementation Project in Ghana. American Journal of Tropical Medicine and Hygiene, 2016, 95, 60-62.	1.4	9
76	In Vivo Imaging of Bioluminescent Mycobacterium ulcerans: A Tool to Refine the Murine Buruli Ulcer Tail Model. American Journal of Tropical Medicine and Hygiene, 2019, 101, 1312-1321.	1.4	9
77	Reliability and validity of the Buruli ulcer functional limitation score questionnaire. American Journal of Tropical Medicine and Hygiene, 2005, 72, 449-52.	1.4	9
78	Assessment and Treatment of Pain during Treatment of Buruli Ulcer. PLoS Neglected Tropical Diseases, 2015, 9, e0004076.	3.0	8
79	Experiences of Pain and Expectations for Its Treatment Among Former Buruli Ulcer Patients. American Journal of Tropical Medicine and Hygiene, 2016, 95, 1011-1015.	1.4	8
80	Neurological and functional recovery inÂtuberculosis patients with spinal cordÂinjury in The Netherlands. NeuroRehabilitation, 2017, 40, 439-445.	1.3	8
81	Buruli ulcer treatment: Rate of surgical intervention differs highly between treatment centers in West Africa. PLoS Neglected Tropical Diseases, 2019, 13, e0007866.	3.0	8
82	Predominance of CTX-M-15-producing ST131 strains among ESBL-producingEscherichia coliisolated from asylum seekers in theÂNetherlands. Journal of Antimicrobial Chemotherapy, 2021, 76, 70-76.	3.0	8
83	A scabies outbreak in the North East Region of Ghana: The necessity for prompt intervention. PLoS Neglected Tropical Diseases, 2020, 14, e0008902.	3.0	8
84	Risk of Measles and Diphtheria Introduction and Transmission on Bonaire, Caribbean Netherlands, 2018. American Journal of Tropical Medicine and Hygiene, 2019, 101, 237-241.	1.4	6
85	What the snake leaves in its wake: Functional limitations and disabilities among snakebite victims in Ghanaian communities. PLoS Neglected Tropical Diseases, 2022, 16, e0010322.	3.0	6
86	Sinus node function in children with congenital complete atrioventricular block. Europace, 2007, 9, 844-847.	1.7	5
87	Serum Levels of Neopterin during Antimicrobial Treatment for Mycobacterium ulcerans Infection. American Journal of Tropical Medicine and Hygiene, 2013, 89, 498-500.	1.4	5
88	Food intake and darunavir plasma concentrations in people living with HIV in an outpatient setting. British Journal of Clinical Pharmacology, 2017, 83, 2325-2329.	2.4	5
89	Treatment for Buruli ulcer: the long and winding road to antimicrobials-first. The Cochrane Library, 2018, 12, ED000128.	2.8	5
90	Darunavir Population Pharmacokinetic Model Based on HIV Outpatient Data. Therapeutic Drug Monitoring, 2019, 41, 59-65.	2.0	5

#	Article	IF	Citations
91	Patients and Medical Staff Attitudes Toward the Future Inclusion of eHealth in Tuberculosis Management: Perspectives From Six Countries Evaluated using a Qualitative Framework. JMIR MHealth and UHealth, 2020, 8, e18156.	3.7	5
92	Multidrug-Resistant Tuberculosis Complicated by Nosocomial Infection with Multidrug-Resistant Enterobacteriaceae. American Journal of Tropical Medicine and Hygiene, 2016, 94, 517-518.	1.4	4
93	Risk factors contributing to a low darunavir plasma concentration. British Journal of Clinical Pharmacology, 2018, 84, 456-461.	2.4	4
94	Buruli ulcer and schistosomiasis: no association found. American Journal of Tropical Medicine and Hygiene, 2004, 71, 318-21.	1.4	4
95	Raltegravir and rifampicin in patients with HIV and tuberculosis. Lancet Infectious Diseases, The, 2014, 14, 1046-1047.	9.1	3
96	The public health control of scabies: priorities for research and action. Lancet, The, 2019, 394, 2068.	13.7	3
97	High varicella zoster virus susceptibility in Caribbean island populations: Implications for vaccination. International Journal of Infectious Diseases, 2020, 94, 16-24.	3.3	3
98	Co-infection of HIV in patients with Buruli ulcer disease in Central Ghana. BMC Infectious Diseases, 2021, 21, 331.	2.9	3
99	Country-specific approaches to latent tuberculosis screening targeting migrants in EU/EEA* countries: A survey of national experts, September 2019 to February 2020. Eurosurveillance, 2022, 27, .	7.0	3
100	Antimicrobial drugs for Buruli ulcer â€“ Authors' reply. Lancet, The, 2010, 375, 1873-1874.	13.7	2
101	Oral treatment for patients with Buruli ulcer co-infected with HIV. Aids, 2014, 28, 797-798.	2.2	2
102	The paediatric participation scale measuring participation restrictions among former Buruli Ulcer patients under the age of 15 in Ghana and Benin: Development and first validation results. PLoS Neglected Tropical Diseases, 2019, 13, e0007273.	3.0	2
103	The African challenge. Lancet, The, 2002, 359, 1527-1528.	13.7	1
104	Poverty-Related Diseases Attack Simultaneously. American Journal of Tropical Medicine and Hygiene, 2016, 94, 939-940.	1.4	1
105	Case Report: Carbapenemase-Producing Enterobacteriaceae in an Asylum Seeker with Multidrugâ€“Resistant Tuberculosis. American Journal of Tropical Medicine and Hygiene, 2018, 98, 376-378.	1.4	1
106	Availability of drugs to admitted patients in Yemeni public hospitals. European Journal of Clinical Pharmacology, 2002, 58, 79-80.	1.9	0
107	Mixing Up All the Results. Critical Care Medicine, 2005, 33, 701-702.	0.9	0
108	Reply to the comment by Dr. Tayek. Intensive Care Medicine, 2006, 32, 1660-1660.	8.2	0

#	Article	IF	Citations
109	The Never Ending Struggle Against Development of Drug Resistance. Clinical Infectious Diseases, 2015, 61, 137-138.	5.8	0
110	Yield of yearly routine physical examination in HIV-1 infected patients is limited: A retrospective cohort study in the Netherlands. PLoS ONE, 2017, 12, e0179539.	2.5	0
111	Skin ulcers misdiagnosed as pyoderma gangrenosum. New England Journal of Medicine, 2003, 348, 1064-6; author reply 1064-6.	27.0	0